Statements in which the resource exists.
SubjectPredicateObjectContext
pubmed-article:16815295rdf:typepubmed:Citationlld:pubmed
pubmed-article:16815295lifeskim:mentionsumls-concept:C0007137lld:lifeskim
pubmed-article:16815295lifeskim:mentionsumls-concept:C0008838lld:lifeskim
pubmed-article:16815295lifeskim:mentionsumls-concept:C0079419lld:lifeskim
pubmed-article:16815295lifeskim:mentionsumls-concept:C0812244lld:lifeskim
pubmed-article:16815295lifeskim:mentionsumls-concept:C0812222lld:lifeskim
pubmed-article:16815295lifeskim:mentionsumls-concept:C0683598lld:lifeskim
pubmed-article:16815295lifeskim:mentionsumls-concept:C0332206lld:lifeskim
pubmed-article:16815295pubmed:issue1lld:pubmed
pubmed-article:16815295pubmed:dateCreated2006-7-11lld:pubmed
pubmed-article:16815295pubmed:abstractTextp73 responds to DNA damage and exerts its pro-apoptotic function. However, p73 might contribute to the development of drug-resistance in certain tumor cells. In this study, we found that p73 and MDM2 correlate with cisplatin-resistant phenotype of human epidermoid carcinoma-derived cells. p73 and MDM2 were kept at low levels in the cisplatin-sensitive KB-3-1 cells, whereas p53 was induced to be phosphorylated at Ser-15 in response to cisplatin. In contrast, p73 and MDM2 were expressed at higher levels, and cisplatin-mediated p53 phosphorylation was undetectable in the cisplatin-resistant KCP-4 cells. Enforced expression of p73 in KB-3-1 cells caused an accumulation of unphosphorylated form of p53 and MDM2, and conferred the cisplatin resistance. Collectively, our results suggest that a loss of the cisplatin sensitivity is at least in part due to a lack of cisplatin-induced p53 phosphorylation, and p73 might cooperate with MDM2 to be involved in this process.lld:pubmed
pubmed-article:16815295pubmed:languageenglld:pubmed
pubmed-article:16815295pubmed:journalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:16815295pubmed:citationSubsetIMlld:pubmed
pubmed-article:16815295pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:16815295pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:16815295pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:16815295pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:16815295pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:16815295pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:16815295pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:16815295pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:16815295pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:16815295pubmed:statusMEDLINElld:pubmed
pubmed-article:16815295pubmed:monthAuglld:pubmed
pubmed-article:16815295pubmed:issn0006-291Xlld:pubmed
pubmed-article:16815295pubmed:authorpubmed-author:OzakiToshinor...lld:pubmed
pubmed-article:16815295pubmed:authorpubmed-author:NakagawaraAki...lld:pubmed
pubmed-article:16815295pubmed:authorpubmed-author:TodoSatoruSlld:pubmed
pubmed-article:16815295pubmed:authorpubmed-author:HosodaMitsuch...lld:pubmed
pubmed-article:16815295pubmed:authorpubmed-author:HayashiSyunji...lld:pubmed
pubmed-article:16815295pubmed:authorpubmed-author:AkiyamaShin-i...lld:pubmed
pubmed-article:16815295pubmed:authorpubmed-author:YoshidaKaoriKlld:pubmed
pubmed-article:16815295pubmed:issnTypePrintlld:pubmed
pubmed-article:16815295pubmed:day18lld:pubmed
pubmed-article:16815295pubmed:volume347lld:pubmed
pubmed-article:16815295pubmed:ownerNLMlld:pubmed
pubmed-article:16815295pubmed:authorsCompleteYlld:pubmed
pubmed-article:16815295pubmed:pagination60-6lld:pubmed
pubmed-article:16815295pubmed:dateRevised2006-11-15lld:pubmed
pubmed-article:16815295pubmed:meshHeadingpubmed-meshheading:16815295...lld:pubmed
pubmed-article:16815295pubmed:meshHeadingpubmed-meshheading:16815295...lld:pubmed
pubmed-article:16815295pubmed:meshHeadingpubmed-meshheading:16815295...lld:pubmed
pubmed-article:16815295pubmed:meshHeadingpubmed-meshheading:16815295...lld:pubmed
pubmed-article:16815295pubmed:meshHeadingpubmed-meshheading:16815295...lld:pubmed
pubmed-article:16815295pubmed:meshHeadingpubmed-meshheading:16815295...lld:pubmed
pubmed-article:16815295pubmed:meshHeadingpubmed-meshheading:16815295...lld:pubmed
pubmed-article:16815295pubmed:meshHeadingpubmed-meshheading:16815295...lld:pubmed
pubmed-article:16815295pubmed:meshHeadingpubmed-meshheading:16815295...lld:pubmed
pubmed-article:16815295pubmed:meshHeadingpubmed-meshheading:16815295...lld:pubmed
pubmed-article:16815295pubmed:meshHeadingpubmed-meshheading:16815295...lld:pubmed
pubmed-article:16815295pubmed:meshHeadingpubmed-meshheading:16815295...lld:pubmed
pubmed-article:16815295pubmed:meshHeadingpubmed-meshheading:16815295...lld:pubmed
pubmed-article:16815295pubmed:meshHeadingpubmed-meshheading:16815295...lld:pubmed
pubmed-article:16815295pubmed:meshHeadingpubmed-meshheading:16815295...lld:pubmed
pubmed-article:16815295pubmed:year2006lld:pubmed
pubmed-article:16815295pubmed:articleTitlep73 and MDM2 confer the resistance of epidermoid carcinoma to cisplatin by blocking p53.lld:pubmed
pubmed-article:16815295pubmed:affiliationDivision of Biochemistry, Chiba Cancer Center Research Institute, Chuoh-ku, Japan.lld:pubmed
pubmed-article:16815295pubmed:publicationTypeJournal Articlelld:pubmed
pubmed-article:16815295pubmed:publicationTypeResearch Support, Non-U.S. Gov'tlld:pubmed
entrez-gene:4193entrezgene:pubmedpubmed-article:16815295lld:entrezgene
entrez-gene:7157entrezgene:pubmedpubmed-article:16815295lld:entrezgene
entrez-gene:7161entrezgene:pubmedpubmed-article:16815295lld:entrezgene
http://linkedlifedata.com/r...entrezgene:pubmedpubmed-article:16815295lld:entrezgene
http://linkedlifedata.com/r...entrezgene:pubmedpubmed-article:16815295lld:entrezgene
http://linkedlifedata.com/r...entrezgene:pubmedpubmed-article:16815295lld:entrezgene